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Introduction: Mesenchymal stem cells (MSCs) are considered to play important roles in wound repair and tissue
remodeling. Hypertrophic scar (HTS) is a cutaneous condition characterized by deposits of excessive amount of
collagen after an acute skin injury. However, currently there is little knowledge about the direct relationship
between MSCs and HTS.
Methods: The hypertrophic scar model was established on rabbit ears. MSCs were isolated from rabbit femur
bone marrow and transplanted through ear artery injection. Hypertrophic scar formation was examined using
frozen-section analysis, hematoxylin and eosin (HE) staining, Masson’s trichrome staining, and scar elevation index.
The role of p53 in the MSCs-mediated anti-scarring effect was examined by gene knockdown using p53 shRNA.
Results: In this study, MSCs engraftment through ear artery injection significantly inhibited the hypertrophic
scarring in a rabbit ear hypertrophic scar model, while this anti-scarring function could be abrogated by p53 gene
knockdown in MSCs. Additionally, we found that MSCs down-regulated the expression of TGF-β receptor I (TβRI)
and alpha-smooth muscle actin (α-SMA) at both mRNA and protein levels in a paracrine manner, and this
down-regulation was rescued by p53 gene knockdown. Moreover, our results showed that MSCs with p53 gene
knockdown promoted the proliferation of fibroblasts through increasing nitric oxide (NO) production.
Conclusions: These results suggest that MSCs inhibit the formation of HTS in a p53 dependent manner through at
least two mechanisms: inhibition of the transformation of HTS fibroblast to myofibroblast; and inhibition of the
proliferation of fibroblasts through inhibition of NO production.Introduction
Hypertrophic scar (HTS) is a common complication of
burn injury and other soft tissue injuries. Cosmetic and
functional impairment caused by HTS remains a great
challenge to burn and plastic surgeons [1,2]. HTS is
characterized by the proliferation of a large number of
fibroblasts, accumulation of collagen and infiltration of
inflammatory cells [3]. Apart from the fibroblasts that
have been recognized as one of the driving factors of
HTS, mesenchymal stem cells (MSCs) were found to
have multiple functions in the formation of HTS [3-5].* Correspondence: thirdforce@163.com
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unless otherwise stated.MSCs are multipotent cells that can migrate to the
wound sites, where they form part of the microenviron-
ment [6-8], improve wound healing and inhibit hyper-
trophic scarring [9-11]. In addition to the differentiation
potential, MSCs can interact with many kinds of cells in
the microenvironment through paracrine signaling path-
ways [12,13]. Activated MSCs can produce abundant
oxidizing agents such as nitric oxide (NO) and cyto-
kines, through which MSCs potently suppress immune
responses and influence tumor cell proliferation and phe-
notype transformation in the tumor microenvironment
[14,15]. However, the mechanisms of the anti-scarring
function of MSCs and the interaction between MSCs and
HTS fibroblast remain poorly understood.
Pathological scar is considered a tumor-like tissue struc-
ture exhibiting an uncontrolled growth manner followings is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tumor-suppressor genes, p53 is also involved in the for-
mation of pathological scar including HTS [16,17]. An ele-
vated p53 protein level was detected in HTS tissue,
compared with normal scar or atrophic white scar [18],
but the exact functions of p53 in the scar formation are
still not clear.
Recently, studying the roles and mechanisms of stromal
cells in tumor formation is a popular field. One study
showed that the p53 gene status in tumor-infiltrating
MSCs influenced the development of tumor [12]; thus it is
an interesting question whether the p53 gene status in
MSCs can influence HTS formation. A better understand-
ing of the roles of p53 gene status in the stromal cells
would probably provide important insight into HTS
pathogenesis. In the present study, we examined the con-
tribution of p53 in MSCs to HTS formation by adminis-
tering MSCs with or without p53 stable knockdown into
rabbit ear HTS models. HTS formation was examined by
frozen-section analysis, hematoxylin and eosin (HE) stain-
ing and Masson’s trichrome staining, and was evaluated
using the scar elevation index (SEI). Our results showed
that wild-type MSCs exerted an anti-scarring effect on the
HTS model, but p53-deficient MSCs had little influence
on the development of HTS. Instead, p53-deficient MSCs
resulted in scar recurrence compared with wild-type
MSCs. Further study showed that p53 knockdown ab-
rogated the capability of MSCs to inhibit the transfor-
mation of HTS fibroblast to myofibroblast. Moreover,
p53 deficiency in MSCs resulted in higher NO produc-
tion, which may promote HTS fibroblast proliferation.
Taken together, our study revealed an important role




Puromycin, NG-monomethyl-L-arginine acetate salt
(L-NMMA) and Griess reagent were from Sigma-Aldrich
(St. Louis, MO, USA). Rabbit p53 shRNA lentiviral par-
ticles, control shRNA lentiviral particles and rabbit
polyclonal antibody against p53 were purchased from
Abiocode Bio-Technology (Shanghai, China). Fluores-
cein isothiocyanate-conjugated antibodies against CD45
and CD90 and phycoerythrin-conjugated antibodies
against CD34 and CD105 were from BD Biosciences
Pharmingen (San Diego, CA, USA). Dexamethasone, as-
corbic acid and β-glycerophosphate were from Sigma-
Aldrich Chemicals (St. Louis, MO, USA). MesenCult
medium with adipogenic stimulatory supplements was
from StemCell Technologies (Vancouver, BC, Canada).
The mouse monoclonal antibody against CD31 and the
rabbit polyclonal antibodies against transforming growth
factor-beta receptor 1 (TβRI) and alpha-smooth muscleactin (α-SMA) were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Recombinant rabbit interferon
gamma and tumor necrosis factor alpha (TNFα) were
from eBiosciences (La Jolla, CA, USA).Ethics statement, rabbits and cell culture
This study was approved by Animal Experimentation
Ethics Committee of the First Afiliated Hospital of
Chengdu Medical College, China. All animal treatments
were carried out in accordance with Guidelines on Care
and Use of Laboratory Animals issued by the Chinese
Council on Animal Research and the Guidelines of
Animal Care.
New Zealand white rabbits were purchased from Ex-
perimental Animal Center of Sichuan Province, with an
initial body weight of 2.0 ± 0.3 kg (for the rabbit ear
model of hypertrophic scarring). Animals were housed
in a regulated environment (22 ± 2°C), with a 12-hour
light/dark cycle (light cycle was from 08:00 to 20:00).
All animals were fed according to the Specific Pathogen
Free Animal Criteria.
MSCs were generated from femur bone marrow using
New Zealand white rabbits (1 month old, male) by the
holo-bone marrow adherence method. In brief, the bone
marrow fluids were extracted under aseptic conditions
and transferred into tube with isopyknic Hanks liquid,
and centrifuged at 1,000 rpm for 5 minutes at 4°C. After
removing supernatant, cells were washed with Hanks li-
quid and cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, 2 mM glu-
tamine, 100 U/ml penicillin and 100 μg/ml streptomycin
(Invitrogen, Carlsbad, CA, USA). Nonadherent cells were
removed 8 hours later, and adherent cells were main-
tained with medium replenishment every 3 days. The
cells reached 90% confluence after 14 to 16 days, and
were passaged at a split ratio of 1:3 to 5. The cells of
passages 4 to 6 were used for experiments. Lineage cell
surface markers (CD34, CD45, CD90, and CD105) were
detected using flow cytometry (BD Accuri C6; Becton
Dickinson San Jose, CA, USA).
HTS fibroblasts were generated from the rabbit ear
HTS tissue. In brief, the rabbit ear HTS tissue was cut
into 0.5 mm pieces and digested with 0.25 g/l dispase II.
The dermal tissue was minced and digested with 30×
volume of collagenase I (200 U/ml) at 37°C for 2 hours,
followed by centrifugation. The cells were collected and
cultured in Dulbecco’s modified Eagle’s medium contain-
ing 15% fetal bovine serum at 37°C in 5% carbon diox-
ide. The culture medium was changed every 3 days. At
80 to 90% confluence, cells were passaged and cultured
in Dulbecco’s modified Eagle’s medium containing 10%
fetal bovine serum. The cells of passages 4 to 6 were used
for further experiments.
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sue is the same as for HTS fibroblast isolation [19]. Ten
days after isolation, the cells in six-well plates were ob-
served using fluorescent microscope. The cells that show
a green fluorescence signal are engrafted MSCs, while
the cells without a green fluorescence signal are HTS fi-
broblasts. The number of fluorescent cells/total cells was
calculated in five randomly selected microscopic fields
(×100) of each well. Three scar tissues from each group
were examined.
Flow cytometry analysis
Cells were trypsinized, washed with phosphate-buffered
saline, and incubated with antibodies against CD34,
CD45, CD90 and CD105. Flow cytometry detection was
performed with a BD Accuri C6 flow cytometer (Becton
Dickinson).
Osteogenic induction and adipogenic induction
For osteogenic induction, cells with 70% confluence
were incubated in osteogenic medium supplemented
with 10−7 M dexamethasone, 0.2 mM ascorbic acid and
10 mM β-glycerophosphate. The medium was changed
twice a week. Cell colonies displayed bone-like nodular
aggregates of matrix mineralization after 14 days in dif-
ferentiation medium. The cells were stained with ali-
zarin red. For adipogenic induction, MesenCult medium
with adipogenic stimulatory supplements was used to
treat the cells. The medium was changed every 3 to
4 days. The cells were stained with oil red after cultur-
ing for 21 days.
Lentivirus transduction
Rabbit bone marrow MSCs were transduced by lentiviral
particles containing rabbit p53 shRNA or control shRNA
for 24 hours, and then subjected to puromycin (3 μg/ml)
selection. Stable clones were harvested 2 weeks later,
and passaged with normal media.
Western blot
Cells were lysed in lysis buffer containing phenylmethyl-
sulfonyl fluoride, leupeptin and other protease inhibitors
for 1 hour on ice. Protein samples were separated on so-
dium dodecyl sulfate–polyacrylamide gels, then trans-
ferred onto polyvinylidene difluoride membranes, and
incubated with corresponding primary antibodies at 4°C
overnight. After washing, membrane was incubated with
secondary antibodies, and subjected to chemiluminescent
detection according to the manufacturer’s instructions.
3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays
Cells were seeded into flat-bottomed 96-well culture plates
at 5,000 cells/well, and grew for 48 hours. Cells were labeledwith the VisionBlue reagent and detected by Synergy 2 mul-
tidetection microplate reader (BioTek, Winooski, VT, USA)
according to the manufacturer’s instruction.
Colony formation assay
Cells were seeded at 2,000 cells/well onto six-well cul-
ture plates and allowed to grow for 12 days before fix-
ation with methanol and staining with crystal violet
(0.5% solution).
Rabbit ear model of hypertrophic scarring, grouping and
MSC engraftment
The rabbit ear model of hypertrophic scarring was estab-
lished according to the procedure previously described by
Kryger and colleagues with a minor modification [20]. In
brief, rabbits were intravenously anesthetized with sodium
pentobarbital 30 mg/kg. Under aseptic operation conditions,
four round wounds each with a diameter of 9 mm were cre-
ated down to the bare cartilage on the ventral surface of
each ear along the long axis. The epidermis, dermis and
perichondrium in each wound were thoroughly removed,
and the wounds were covered with sterile gauze for 1 day.
After this operation, the rabbits were provided with conven-
tional anti-inflammatory treatment. Three weeks after oper-
ation, the healed wound surface showed an obvious
protrusion, an indicator of HTS formation. Five weeks post
operation, the formation of HTS reached the peak level.
Twelve rabbits were divided into three groups with
age and gender matched: control group; control shRNA
MSC group; and p53 shRNA MSC group. Three days
after the model operation, 1 × 105 cells of control shRNA
MSCs or p53 shRNA MSCs (in 1 ml phosphate-buffered
saline) were injected into the rabbits via ear artery once
every 2 days up to eight times. Phosphate-buffered saline
was used in the control group.
General observation and histological analysis
General observations including growth status, color, tex-
ture and thickness of HTS were recorded by photogra-
phic imaging at designated time points. In addition, the
height of HTS was measured.
Full-thickness biopsies of the wound-repair bed and
surrounding tissue were obtained at 3, 4 and 5 weeks
after operation. The tissues were subjected to frozen-
section analysis. Paraffin sections were subsequently sub-
jected to HE staining, and Masson’s trichrome staining
using Masson’s Trichrome Stain Kit (KeyGen Biotech
Co., Nanjing, China) following the manufacturer’s instruc-
tions. In brief, the sections were stained in Weigert’s
iron hematoxylin working solution for 10 minutes and
in Biebrich scarlet-acid fuchsin solution for 5 minutes,
and then placed in 1% phosphomolybdic–phosphotungstic
acid solution for 5 minutes. The sections were then
stained in aniline blue solution for 5 minutes, and rinsed
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were stained blue. Keratin and muscle fibers were stained
red. Cell cytoplasm and nuclei were stained light pink and
dark brown, respectively. In each section of Masson’s
trichrome staining, three high-power fields in the der-
mis of wound area or unwounded normal tissue, infer-
iorly by the ear cartilage and superiorly by the epithelial
basement membrane, were randomly selected and photo-
graphed. The integrated optical density analysis of Mas-
son’s trichrome staining was performed by Image-Pro Plus
6.0 software (Media Cybernetics, Silver Springs, MD,
USA) [21].
The SEI, which measures the ratio of total scar con-
nective tissue area to the area of underlying dermis, was
evaluated using Image-Pro Plus 6.0 software. The height
of the underlying dermis was determined based on the
height of the adjacent unwounded dermis. An SEI of
1 indicated no newly formed hypertrophied dermis,
whereas SEI >1 denoted HTS formation [22]. CD31 in the
scar tissues was detected by immunohistochemistry using
monoclonal anti-CD31 antibody (1:100).
Real-time PCR
Total RNA was isolated using RNAprep pure Cell/
Bacteria Kit (Tiangen Biotech, Beijing, China), and first-
strand cDNA synthesis was performed using the 1st
cDNA Synthesis Kit with oligo(dT)15 (Tiangen Biotech).
The mRNA levels were measured by real-time PCR using
SYBR Green Master Mix (Roche Diagnostics, Indianapo-
lis, IN, USA). The total amount of mRNA was normalized
to endogenous β-actin mRNA.
Sequences of PCR primer pairs were as follows: TβRI,
forward primer 5′-TGTTGGTACCCAAGGAAAGC-3′
and reverse primer 5′-CACTCTGTGGTTTGGAGC
AA-3′; α-SMA, forward primer 5′-CAGGGAGTAATG
GTTGGAAT-3′ and reverse primer 5′-TCTCAAACA-
TAATCTGGGTCA-3′; inducible nitric oxide synthase
(iNOS), forward primer 5′-CAGCTGGGCTCAACAA
ACCTT-3′ and reverse primer 5′-CATTGGAATGGA
AGCGTATCG-3′; and β-actin, forward primer 5′-GC
TATTTGGCGCTGGACTT-3′, and reverse primer 5′-
GCGGCTCGTAGCTCTTCTC-3′.
Detection of nitric oxide
NO was detected using a modified Griess method. Briefly,
all NO3
− was converted into NO2
− by nitrate reductase, and
total NO2
− was detected by the Griess reaction [23].
Statistical analysis
SPSS Version 13.0 for Windows (SPSS Inc., Chicago, IL,
USA) was used for data analysis. Data were presented as
the mean ± standard error of the mean. Statistical signifi-
cance was assessed by one-way analysis of variance. Sig-
nificance was set at P <0.05.Results
Establishment of the p53 stable knockdown cell line of
rabbit MSCs
Passage 4 of MSCs was transduced with lentiviral particles
containing p53 shRNA or control shRNA, each with a green
fluorescent protein label. After transduction, cells were se-
lected with puromycin, then passaged for further use
(Figure 1A). p53 knockdown was successfully achieved as
shown by western blot. The expression of p53 protein
decreased more than 80% (Figure 1B,C). 3-(4,5-di-
methylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) and colony
formation assays were performed to test the cell viabil-
ity and colony formation capacity of p53 shRNA-
transduced or control shRNA-transduced cells. There
was no significant difference between the two groups
on 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphe-
nol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and colony
formation (Figure 1D,E,F). CD90 and CD105 were
highly expressed in both p53 shRNA-transduced and
control shRNA-transduced MSCs. CD34 and CD45
expressions were very low in the above cells (Fig-
ure 1G). Both kinds of cells would differentiate into
mineralizing cells stained by alizarin red after osteo-
genic induction or adipocytes stained by oil red after
adipogenic induction (Figure 1H). These results sug-
gested that p53 shRNA-transduced and control
shRNA-transduced MSCs maintained the common fea-
tures of MSCs.Exogenous MSCs migrated into rabbit ear hypertrophic
scar tissue by transplantation via ear artery
Endogenous MSCs are known to be recruited to the
sites of damaged tissue, while exogenous MSCs have
also been shown to migrate to target tissue by trans-
plantation via associated artery or by bone marrow
transplantation [12,24]. In this study, to examine
whether exogenous MSCs were recruited into the HTS
tissue after transplantation via ear artery, MSCs with or
without p53 stable knockdown, both with a green fluor-
escent protein label, were injected into the rabbit ear via
the ear artery during the wound healing process in the
rabbit ear HTS model. Scars were excised and subjected
to frozen-section analysis and HE staining 4 weeks after
model operation. The green fluorescence in the frozen
sections indicated the presence of the transplanted
MSCs that migrated into the scar tissue (Figure 2A).
MSCs were also isolated from the scar tissue and cul-
tured in the media. A fraction of the scar tissue-
infiltrated MSCs expressed green fluorescent protein in
both p53 shRNA-transduced and control shRNA-
transduced cells (14.8% ± 0.9, and 15.3 ± 0.7 respect-
ively) (Figure 2B).
Figure 1 Establishment of p53 stable knockdown in rabbit mesenchymal stem cells. Passage 4 of mesenchymal stem cells (MSCs)
generated from femur bone marrow was transduced with lentiviral particles containing p53 shRNA or control (Ctrl) shRNA. (A) Stable clones were
harvested after puromycin selection, and cells of passages 3 to 9 were used for the following tests. Scale bar, 500 μm. (B) Representative western
blot image of p53 in MSCs. (C) Quantification of p53 protein level in western blot by densitometry. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) used as internal control (n = 3, *P <0.01 vs. control group). (D) 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) assay showed no significant difference in cell viability between the two groups. P >0.05. (E) Representative images of cell
colony formation. Viable cells (2,000 cells/well in six-well plates) were allowed to grow for 12 days before being fixed with methanol and stained
with crystal violet. Scale bar, 1 cm. (F) Quantification of the number of colony formation in p53 shRNA and control shRNA groups. P >0.05. (G)
Flow cytometry analysis of cell surface markers. Blue line, negative control. (H) Differentiation capacity of the cells. Both control shRNA-transduced
and p53 shRNA-transduced MSCs differentiated into mineralizing cells stained with alizarin red, or adipocytes stained with oil red. Scale bar,
200 μm. Data presented as mean ± standard error of the mean, n = 3 individual experiments.
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hypertrophic scar formation in the rabbit ear model
The control group without MSC treatment showed
successful HTS formation after operation characterized
by obvious hyperplasia, collagen fiber accumulation
and abundant blood vessels, according to the general
observations and histological analysis (Figure 3A,B,C,D,
first panel). MSCs transduced with control shRNA in-
hibited the HTS formation (Figure 3A,B). The SEI was
significantly reduced in control shRNA-transduced
MSCs group at 3, 4 and 5 weeks after model operation
compared with control group without MSCs and thep53 shRNA-transduced MSC group (Figure 3E). The
control shRNA-transduced MSC group showed less
collagen deposition, indicated by lighter Masson’s tri-
chrome staining (Figure 3C,F) and less CD31-positive
blood vessels (Figure 3D) by immunohistochemistry com-
pared with the control group without MSCs and the p53
shRNA-transduced MSC group. However, there was no
significant difference in the SEI and histological results be-
tween the p53 shRNA-transduced MSC group and the
normal control group. Taken together, the results indi-
cated that MSCs significantly inhibited the development
of HTS and that p53 knockdown abrogated the effects of
Figure 2 Mesenchymal stem cells with or without p53 stable knockdown, both with green fluorescent protein label, were injected via
ear artery during the wound healing process of the rabbit ear hypertrophic scar model, and migrated into the scar tissue. (A) Frozen-
section analysis and hematoxylin and eosin (HE) staining of scars 4 weeks after model operation. The green fluorescence in the frozen sections
indicated the presence of the transplanted mesenchymal stem cells (MSCs) that migrated into the scar tissue. Scale bar, 200 μm. (B) Representative
cultured MSCs that were isolated from the scar tissue. Scale bar, 200 μm. Ctrl, control; GFP, green fluorescent protein.
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sential for MSCs to prevent HTS formation.
TβRI and α-SMA in fibroblast were downregulated by
MSCs in a p53-dependent manner
Transformation of fibroblast to myofibroblast is an import-
ant step in HTS development. During the differentiation,
fibroblastic cells lose their migratory phenotype and be-
come sessile. Previous studies have shown that the differ-
entiation of scar fibroblast relies on transforming growth
factor-beta 1 (TGF-β1) and α-SMA [25]. The TβRI could
recognize and bind to TGF-β1 complex in the fibroblasts,
and activate the following signaling pathways. We found
that conditioned medium from control shRNA-transduced
MSCs significantly downregulated TβRI and α-SMA in
both mRNA (Figure 4A) and protein (Figure 4B,C) le-
vels, while the conditioned medium from p53 shRNA-
transduced MSCs did not affect the expression of TβRI
and α-SMA. Our results indicated that the transformation
of fibroblast to myofibroblast could be inhibited by MSCs
through paracrine in a p53-dependent manner.Elevated level of nitric oxide produced by p53-deficient
MSCs may be responsible for the promotion of HTS
fibroblast proliferation
It was reported that p53 could decrease iNOS expression
in certain murine fibroblasts and MSCs by downregula-
ting iNOS promoter activity [26]. After treatment with
interferon gamma and TNFα, iNOS mRNA expression in
p53 knockdown MSCs was significantly increased compared
with control shRNA-transduced MSCs (Figure 5A). NO
production was enhanced in p53 knockdown MSCs com-
pared with control shRNA-transduced MSCs (Figure 5B).
To examine the roles of NO in the proliferation of HTS fi-
broblasts, L-NMMA – an iNOS inhibitor – was used to
manipulate the NO level in the conditioned medium from
MSCs with or without p53 knockdown. L-NMMA signifi-
cantly ablated the promotion of fibroblast proliferation
caused by the conditioned medium from p53 knockdown
MSCs (Figure 5C). These results suggested that the ele-
vated production of iNOS and NO by p53 deficiency
MSCs may be responsible for the promotion of HTS
fibroblast proliferation.
Figure 3 Role of p53 in mesenchymal stem cell-induced prevention of hypertrophic scar in the rabbit ear model. Representative (A)
general observations (scale bar, 5 mm), (B) hematoxylin and eosin staining (scale bar, 500 μm), (C) Masson’s trichrome staining (scale bar, 200 μm),
and (D) immunohistochemistry of CD31 (scale bar, 200 μm) of scar sections 4 weeks after model operation from three individual experiments. (E) Scar
elevation index (SEI). (F) Integrated optical density analysis of Masson’s trichrome staining. Data expressed as mean ± standard error of the mean, n = 6.
*P <0.05 vs. control (Ctrl) group and p53 shRNA mesenchymal stem cell (MSC) group.
Figure 4 TβRI and α-SMA of fibroblasts were downregulated by mesenchymal stem cells in a p53-dependent manner. Fibroblasts
derived from rabbit ear hypertrophic scar were treated with or without conditioned medium from control shRNA mesenchymal stem cells (MSCs)
or p53 shRNA MSCs for 48 hours. The (A) mRNA and (B,C) protein levels of TβRI and α-SMA were determined by real-time PCR and western blot.
n = 3, *P <0.05 vs. untreated group, p53 shRNA group. Data shown are representative of three individual experiments. α-SMA, alpha smooth
muscle actin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TβRI, transforming growth factor-beta receptor 1.
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Figure 5 Elevated nitric oxide level produced by mesenchymal stem cells with p53 deficiency may be responsible for the proliferation
promotion of hypotrophic scar fibroblasts. Mesenchymal stem cells (MSCs) with or without p53 knockdown were treated with or without
interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα) (10 ng/ml each) for 24 hours. (A) Inducible nitric oxide synthase (iNOS) mRNA
was measured by real-time PCR. (B) Total nitrate was measured by Griess. (C) Conditioned medium from MSCs treated with IFNγ and TNFα for
24 hours was added to cultured hypertrophic scar fibroblasts with or without treatment with 1 mM NG-monomethyl-L-arginine acetate salt
(L-NMMA). Cells were trypsinized and counted 48 hours later on the indicated days. n = 3, *P <0.05 vs. p53 shRNA group. Data shown are
representative of three individual experiments. Ctrl, control.
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The formation of HTS is considered a result of aberrations
of wound healing following any injury to the deep dermis,
including burn injury, lacerations, abrasions, surgeries,
and so on. Any factor that delays wound healing would in-
crease the chance of hypertrophic scarring. On the con-
trary, if the process of wound healing is accelerated, the
occurrence or degree of scarring would be reduced [2,3].
As known, the time to heal is the most important factor
to predict the development of HTS in a burn wound. If
healing occurred between 14 and 21 days, only one-third
of anatomical sites became hypertrophic. However, 78% of
the sites developed HTS if the burn wound healed after
21 days. The time to heal could influence many other fac-
tors involved in HTS formation, including transformation
of the wound clot into granulation tissue, which requires a
delicate balance between extracellular matrix protein de-
position and degradation [27]. Stem cells have been regar-
ded as a potentially useful agent for promoting wound
healing. Specifically, bone marrow MSCs were shown to
improve wound healing in several studies [4,5]. Human
bone marrow MSCs prevented HTS formation in the rab-
bit ear HTS model via inflammatory regulation and se-
cretion of an anti-inflammatory protein, TNFα-stimulated
gene/protein 6 [28]. The immune-modulating properties,
especially the immune-suppression effect, of MSCs have
made it widely applicable, although the mechanisms re-
main unclear. Our current study shows that transplan-
tation of MSCs via the rabbit ear artery is an effective
approach for MSC engraftment and migration in the
rabbit HTS model. Furthermore, MSCs engraftment sig-
nificantly reduced the formation of rabbit ear HTS, sug-
gesting that MSCs may have potential clinical applications
in modulating the process of wound healing. In addition,
we also found less infiltrated inflammatory cells in the scar
tissue with HE staining in the control shRNA-transduced
MSC group. Although we focus on p53 in the presentstudy, further investigation about inflammatory modula-
tion of MSCs would be performed in the future.
The aberration of gene expression in HTS has been
well studied, but the most critical genes in HTS progres-
sion remain undefined [29-31]. In the HTS tissue, p53
protein was reported to have a higher level compared
with normal dermis tissue [18], but the roles of p53 in
HTS have not been fully investigated, and little is known
about p53 gene status in MSCs in the HTS tissue. Inves-
tigators recently found that MSCs could interact with
other types of cells in the microenvironment, resulting in
gene expression or even the phenotype changes of those
cells; for example, the epithelial–mesenchymal transition
of tumor cells [32-35]. Interestingly, the gene status of p53
in the MSCs has been reported to play an essential role in
tumor development [12]. We therefore hypothesized that
the p53 in MSCs plays an important role in wound healing
and then the development of HTS. To test this hypothesis,
we established MSCs with stable p53 knockdown, and
transplanted them into the rabbit ear HTS model. We
found that the engraftment of p53-deficient MSCs can
hardly inhibit the scar formation, suggesting that p53 plays
an essential role in preventing HTS formation by MSCs.
According to this result, the higher expression level of
p53 in the HTS tissue as previously reported may be
the outcome of self-regulation of anti-scarring in the
microenvironment.
Central to the formation of HTS tissue is the transform-
ation of HTS fibroblast to myofibroblast [36], the latter
being responsible for the excessive deposition and irre-
versible remodeling of the extracellular matrix [37]. The
TGF-β1 signaling pathway and α-SMA are involved in the
phenotype transformation [38,39]. Our results showed
that wild-type MSCs downregulated the expression of
TβRI and α-SMA at both the mRNA and protein levels in
a paracrine manner, while the p53-deficient MSCs did not
affect the expression of these two genes. These data
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myofibroblast may account for the anti-scarring outcome
by MSC engraftment, in a p53-dependent manner. How-
ever, the mechanisms of MSCs regulating the expression
of TβRI and α-SMA of fibroblasts are still unclear. Further
investigations on these mechanisms will be helpful for un-
derstanding the role of MSCs in HTS formation.
The roles of oxidative/nitrosative stress in cell prolife-
ration are controversial [40-42]. Our previous studies
showed that the oxidization level in HTS tissue is ele-
vated compared with normal tissue [43]. In this study,
we used interferon gamma and TNFα as stimulation for
MSCs to produce NO before collecting conditioned me-
dium. Our data suggest that the elevated level of NO pro-
duced by MSCs with p53 knockdown is involved in the
proliferation promotion of HTS fibroblasts, and MSCs
could inhibit the transformation of HTS fibroblast to
myofibroblast in a p53-dependent manner.
Conclusions
The results in the current study demonstrated that wild-
type MSC engraftment could inhibit the formation of
HTS, in a p53-dependent manner. This effect might be
achieved through downregulating TβRI and α-SMA gene
expression, and inhibiting the transformation of HTS fibro-
blast to myofibroblast through reducing NO production.
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